- Home
- MODD vs ACRV Comparison
MODD vs ACRV Comparison
Compare MODD & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- ACRV
- Stock Information
- Founded
- MODD 1998
- ACRV 2018
- Country
- MODD United States
- ACRV United States
- Employees
- MODD N/A
- ACRV N/A
- Industry
- MODD Industrial Specialties
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- MODD Health Care
- ACRV Health Care
- Exchange
- MODD Nasdaq
- ACRV Nasdaq
- Market Cap
- MODD 46.3M
- ACRV 36.1M
- IPO Year
- MODD N/A
- ACRV 2022
- Fundamental
- Price
- MODD $0.86
- ACRV $1.05
- Analyst Decision
- MODD
- ACRV Buy
- Analyst Count
- MODD 0
- ACRV 7
- Target Price
- MODD N/A
- ACRV $17.60
- AVG Volume (30 Days)
- MODD 78.5K
- ACRV 728.6K
- Earning Date
- MODD 06-20-2025
- ACRV 05-14-2025
- Dividend Yield
- MODD N/A
- ACRV N/A
- EPS Growth
- MODD N/A
- ACRV N/A
- EPS
- MODD N/A
- ACRV N/A
- Revenue
- MODD N/A
- ACRV N/A
- Revenue This Year
- MODD N/A
- ACRV N/A
- Revenue Next Year
- MODD N/A
- ACRV N/A
- P/E Ratio
- MODD N/A
- ACRV N/A
- Revenue Growth
- MODD N/A
- ACRV N/A
- 52 Week Low
- MODD $0.68
- ACRV $1.05
- 52 Week High
- MODD $2.65
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- MODD 39.61
- ACRV 31.03
- Support Level
- MODD $0.75
- ACRV $1.06
- Resistance Level
- MODD $0.90
- ACRV $1.19
- Average True Range (ATR)
- MODD 0.07
- ACRV 0.09
- MACD
- MODD -0.01
- ACRV 0.05
- Stochastic Oscillator
- MODD 39.29
- ACRV 0.00
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.